Elanco has announced the results of a challenge study which the company says demonstrates the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course1.
The study…
Elanco Animal Health has highlighted the results of a new study1 which concludes that Duvaxyn IE-T Plus stimulates a highter protective antibody response than four other equine influenza vaccines commercially available in Ireland.
The trial compared the…
Elanco Companion Animal Health has announced that its Duvaxyn IE and IE-T Plus vaccines have been licensed for active immunisation against OIE recommended clade 1 and clade 2 equine influenza strains, the first vaccines to be so licensed.
The company…
Elanco Animal Health has launched Vulketan, a POM-V sterile topical gel developed to encourage the healing of equine wounds.
Vulketan contains ketanserin - a serotonin-S2 antagonist.2 Elanco says that although serotonin is more widely known as a neurotransmitter…